Navigation Links
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/11/2008

oducts and new therapies; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; failure of third-party manufacturers to produce the product volumes required on a timely basis and fluctuations in currency exchange rates. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Pharmion Corporation; MethylGene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
8. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015  Daktari Diagnostics was honored at the ... in the Service of Society Award. IEEE President and CEO, ... L. Shoop presented the award to Principal Scientist ... was held Saturday, June 20, 2015, at the historic Waldorf ... "I have spent more than 3 years ...
(Date:6/29/2015)... ZIONA, Israel , June 29, 2015 ... TASE: BVXV) today announced positive preliminary results from its ... for a universal influenza vaccine. In this trial, M-001 ... 50 to 65, followed by an administration of the ... M-001 was found to be safe and well tolerated ...
(Date:6/29/2015)... , June 29, 2015 Regeneron Pharmaceuticals, ... the Proceedings of the National Academy of ... that the Company,s proprietary VelociGene ® and ... and preclinical validation of potential candidates that could ... Middle East Respiratory Syndrome (MERS). This involved the ...
Breaking Medicine Technology:Daktari Honored with IEEE Spectrum Award 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 2Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 3Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 4Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication 5
... MedVantx, Inc., the company that created first ever controlled access ... Inc. Magazine has rated the company as one of the ... year in a row, MedVantx has made the list.  In ... thirteenth overall. The Inc. 500/5000 list is the ...
... 2011 CORPAK MedSystems, Inc., a leading ... enteral feeding and bedside-technology markets, today announced the appointment ... officer. Mr. Blair brings 40 years ... recently as the chairman and chief executive officer of ...
Cached Medicine Technology:MedVantx Honored by Inc. 500/5000 Three Years in a Row 2CORPAK MedSystems Names Jeffrey Blair Chief Executive Officer 2CORPAK MedSystems Names Jeffrey Blair Chief Executive Officer 3
(Date:6/30/2015)... ... , ... New Xarelto lawsuit claims proposed for consolidation in ... according to attorneys handling Xarelto lawsuits included in the MDL.* The ... for plaintiffs’ attorneys in filing new claims, according to court documents. Drafts of ...
(Date:6/30/2015)... ... June 30, 2015 , ... AvePoint, the established leader in ... new apps – AvePoint Watermark, AvePoint MyWorld, and AvePoint ... apps, workers can better streamline everyday business operations and take advantage of the latest ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... be held October 28-31, 2015 at Disney’s Coronado Springs Resort in Lake Buena ... and networking. Each year, this premiere event for psychiatric-mental health nursing draws more ...
(Date:6/30/2015)... ... ... This Fourth of July, Peacock Alley celebrates the American ideals ... perseverance, commitment to quality, honesty and love of friends and family. These are the ... love of quilts, Peacock Alley was fully realized and grown while raising her family. ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 2Health News:Xarelto Lawsuit News: New Xarelto Lawsuit Filings to Be Expedited 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 4Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2
... future hospital development , , OAKBROOK ... The Joint Commission offers guiding principles and actions for the hospital ... sicker patients, patient safety and quality of care, economics and the ... to meet these demands. , , ...
... improved compliance more than paper and pencil , , THURSDAY, Nov. ... their fingers do the texting will increase compliance with the ... dieting. , As a first proof that such a method ... that kids aged 5 to 13 are almost twice as ...
... in Annual LocumTenens.com Survey , ... ... closer third-party-payer scrutiny of rising imaging costs, many radiologists fear ... medical practices. More than half (52 percent) of radiologists responding ...
... Nov. 20, 2008 AMERIGROUP,Corporation (NYSE: AGP ... from Centene Corporation, principally the right to provide managed ... In a related,transaction, AMERIGROUP plans to sell certain assets ... to AMERIGROUP,s Medicaid members in,South Carolina. At the ...
... WOODLAND HILLS, Calif., Nov. 20 Unemployment continues to,grow nationwide, ... the employees who aren,t laid off -- the ones now ... Many are battling sleeplessness.,It,s a problem costing businesses productivity and ... to help employers do something,about it. , ...
... 20 As part of its mission to spur,research ... population, The SCAN Foundation announced today it has awarded ... between health,professionals, policymakers, and the public about how to ... to fund two (2) special,projects related to long-term care ...
Cached Medicine News:Health News:'Hospital of the Future' Report Urges Major Changes 2Health News:'Hospital of the Future' Report Urges Major Changes 3Health News:'Hospital of the Future' Report Urges Major Changes 4Health News:'Hospital of the Future' Report Urges Major Changes 5Health News:Texting Food Diaries Helps Kids Stick With Diets 2Health News:Texting Food Diaries Helps Kids Stick With Diets 3Health News:Radiologist Salary Survey Shows Fear of Universal Healthcare 2Health News:Radiologist Salary Survey Shows Fear of Universal Healthcare 3Health News:AMERIGROUP to Acquire New Jersey Medicaid Business, Sell Medicaid Business in South Carolina 2Health News:AMERIGROUP to Acquire New Jersey Medicaid Business, Sell Medicaid Business in South Carolina 3Health News:Scent To Sleep Offers Help for Companies Losing Time, Money to Microsleep 2Health News:The SCAN Foundation Announces New Grants Aimed at Refocusing the Debate About Healthcare for Seniors 2